NEW YORK (GenomeWeb News) — Roche said today that it has acquired Iquum, a privately held company developing point-of-care molecular diagnostics.

Under the terms of the agreement, Roche will pay Iquum shareholders $275 million upfront and up to $175 million in contingent product-related milestones. Once the transaction is complete, pending customary closing conditions, Marlborough, Mass.-based Iquum will be integrated into Roche Molecular Diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.